Soligenix Inc SEC Filings

Soligenix Schedule 13G summary: This filing reports that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC (the Reporting Persons) each may be deemed to beneficially own 446,408 shares of Soligenix common stock, representing 4.99% of the class as of the close of business on October 1, 2025. The filing explains ownership arises from warrants issued under a Securities Purchase Agreement dated September 25, 2025 and details earlier potential beneficial ownership figures tied to issuance and exercise of three warrants and a contemplated issuance of 425,000 shares to Intracoastal at closing. Blocker provisions in the warrants limit exercise to remain at or below specified ownership thresholds.

Soligenix, Inc. is offering 4,064,080 shares of common stock, pre-funded warrants to purchase 1,491,480 shares and common warrants to purchase 5,555,560 shares at a public offering price of $1.35 per share (common warrants exercise price $1.35; pre-funded warrants exercise price $0.001). Net proceeds are estimated at approximately $6.8 million to fund R&D, commercialization activities and general corporate purposes. The offering is intended to address Nasdaq noncompliance after receiving a notice for failing to meet the $2.5 million stockholders' equity listing requirement; Soligenix estimates needing at least $3.4 million net proceeds to regain compliance. The prospectus discloses a going concern warning, limited cash runway into Q4 2025 absent new funding, no minimum offering close and potential dilution from existing warrants, options and future issuances.

Soligenix, Inc. is a clinical-stage biopharma with two operating segments: Specialized BioTherapeutics and Public Health Solutions. The company has no approved products and reported for the six months ended June 30, 2025 a net loss of $5,653,244 and used $4,588,835 of cash in operating activities, with working capital of $1,691,345. As of June 30, 2025 the company had 3,504,950 shares issued and outstanding and significant potential dilution from 1,467,581 warrants, 300,467 options (112,332 vested) and 5,929,412 shares available under the 2025 Equity Incentive Plan. Recent financing activity included issuance of 780,620 ATM shares at a weighted average price of $1.84 for gross proceeds of ~$1.44M. Management expects to pursue additional equity, grant/contract funding, partnerships, or other strategic transactions but states uncertainty about obtaining sufficient capital. The filing discloses an auditor going-concern opinion and substantial risks tied to government funding, clinical/regulatory outcomes, third-party manufacturing, and market acceptance.

Form 4 filing reveals that Anthony Gregg Lapointe, Director of Soligenix, received a stock option grant on June 20, 2025. The derivative securities transaction details include:

• Granted 17,647 stock options to purchase common stock
• Exercise price set at $1.70 per share
• Options expire on June 20, 2035
• Vesting schedule occurs in four equal installments: - September 20, 2025 - December 20, 2025 - March 20, 2026 - June 20, 2026

This grant represents standard director compensation and indicates continued board engagement. The 10-year option term provides long-term alignment with shareholder interests.

Form 4 Filing Details: Jerome B. Zeldis, Director of Soligenix (SNGX), reported the acquisition of stock options on June 20, 2025. The insider was granted 17,647 stock options with an exercise price of $1.70 per share.

The options have a 10-year term expiring on June 20, 2035, and will vest in four equal installments on:

• September 20, 2025
• December 20, 2025
• March 20, 2026
• June 20, 2026

This equity-based compensation grant aligns the director's interests with shareholders through long-term stock ownership potential. The filing was reported within the required SEC timeline, demonstrating compliance with Section 16(a) reporting obligations.